A patient opens her phone and shows you a Seoul clinic’s treatment menu. She is not asking you to fill a fold. She is asking whether you can do what they do — and she has a product name, a cadence and a price in mind already.
For an owner or operator, that consultation is an operations problem before it is a clinical one. And much of what circulates about Korean aesthetics is wrong in ways that cost credibility in front of an informed patient, so the figures below are worth knowing precisely. This is the operator’s view of the wider K-beauty influence on U.S. aesthetic medicine.
Where your patients’ new reference points come from
Korea’s Ministry of Health and Welfare reported that Korea treated 2.01 million foreign patients in 2025 — the first time the figure has passed two million since national tracking began in 2009, and a 71.9% increase on the 1.17 million treated in 2024, which had itself roughly doubled the 610,000 of 2023. China and Japan were the largest source countries and the United States fourth.
The composition matters more than the headline. In government figures reported by Korean trade press, dermatology was the largest specialty in 2025 at about 1.31 million patients, or 62.9% of the total, with plastic surgery second at 11.2%. In 2024, clinics rather than hospitals treated 82.0% of foreign patients, and the Seoul metropolitan area 85.4%.
The dominant experience of Korean aesthetic care, then, was not surgery in a hospital; it was a skin procedure in an outpatient clinic, probably repeated. So “what they do in Korea” usually means skin — tone, texture, pore appearance, laxity, surface light — and an assumption that treatment is frequent, incremental and unremarkable. Korean press describes the same habit, one Korea Times feature noting that booking a laser or a skin booster “has become almost as routine as booking a haircut.” That describes a market, not better outcomes.
The demand curve is moving toward skin work
The clearest commercial signal is the International Society of Aesthetic Plastic Surgery’s survey of procedures performed in 2024. Total aesthetic procedures fell 4.8% on ISAPS’s own numbers, surgical down 6.7% and non-surgical down 3.1%. Within that decline, botulinum toxin dropped 17.4% and hyaluronic acid fillers grew only 5.2%, while non-surgical skin tightening rose 38.9%, chemical peels rose 33.3% and total facial rejuvenation rose 42.0%.
Handle them carefully. ISAPS is a voluntary member survey with extrapolation, not a census: 2,975 plastic surgeons supplied 2024 data, added procedure categories may affect comparability with prior years, and it counts plastic surgeons only, undercounting non-surgical volume. South Korea is not reported as an individual country in those statistics, so the “Korea ranks fifth for procedures” line circulating online does not come from ISAPS.
The U.S. consumer side agrees. In the American Society for Dermatologic Surgery’s 2025 survey of more than 3,500 consumers, skin texture and/or discoloration registered at 78% — tied with lines around and under the eyes, behind only excess body weight at 85%. That is a consumer survey, not a physician survey. Either way the growth is in skin-directed categories a well-equipped practice can already deliver, and a practice built entirely on toxin and filler units carries concentration risk in a year when toxin volume fell.
What “filler fatigue” is, and what it is not
You will be sold this trend with a statistic. Decline it. No survey from the American Academy of Facial Plastic and Reconstructive Surgery, the American Society of Plastic Surgeons or the American Society for Dermatologic Surgery publishes a figure for how many patients request filler dissolution, so any “X% of injectors are dissolving more filler than they inject” attributed to a society is unsourced trade commentary.
The strongest society-sourced proxy is narrower than the narrative. In the AAFPRS 2023 member survey, 24% of responding surgeons said looking unnatural or “overdone” is their patients’ biggest fear when considering a facial procedure. It polled a select group of the academy’s members with no published sample size, so it is member perception rather than a patient statistic — and it is the ceiling of what can be claimed. AAFPRS’s 2025 release makes the point qualitatively only, reporting that patients “aren’t asking for more drastic changes – they are seeking natural-looking and thoughtfully planned approaches.” Do not turn that into a percentage.
There is a market signal, and it should be labeled as one: AbbVie reported full-year 2025 global Juvéderm® net revenues of $993 million, down 15.3%, with Botox® Cosmetic down 4.3%. One manufacturer’s revenue is shaped by pricing, loyalty programs and destocking as much as by taste, so it supports “HA filler demand softened,” not “patients are dissolving their filler.”
What is clinically real is the complication: facial overfilled syndrome is a named entity in the peer-reviewed literature, managed with targeted hyaluronidase. Stop selling volume as the default, and be able to discuss an overtreated appearance without flinching.
Scripting the “can you do what they do in Korea?” consultation
Establish which of three requests it actually is
The question compresses three asks. Some patients want a look: even surface light, fine texture, no obvious intervention. Some want a named product they read about or received abroad. Some want a cadence — short, frequent visits instead of an annual event. Only the second has a regulatory answer, and treating a cadence request as a product request loses the case.
Then answer in a fixed order. Assessment first: what is driving the appearance she describes — barrier and hydration, surface texture, pigment distribution, laxity, or volume and structure. Then what your practice can do about each, in what sequence, over how many visits. Only then, if a product was named, its U.S. status — leading with the refusal makes the practice sound unable rather than accurate. The measurable components are in our breakdown of what “glass skin” means in measurable terms.
Ready to put this into practice?
Explore Empire's hands-on, CME-accredited Practice Development & Business Strategies courses — live patients, expert faculty, and ongoing mentorship.
Her expectations about product claims are not confusion
Korea has a legally defined middle category between cosmetics and drugs: its Cosmetics Act Enforcement Rule recognizes 11 functional-cosmetic claim categories, reviewed or filed before marketing, including wrinkle improvement, prevention of melanin deposition and relief of hair-loss symptoms. In the United States those same claims would generally make a product an unapproved new drug. She has been shopping in a system that permits pre-reviewed efficacy claims on a cosmetic, so she is calibrated to different rules — and saying so is disarming.
Declining an unapproved product without losing the patient
Get the vocabulary right. Off-label describes an approved product used outside its labeled indication; unapproved means no U.S. approval exists at all. Most of the Korean and European products patients name sit in the second category, and calling them off-label is indefensible in a board complaint.
- Exosome products. There are currently no FDA-approved exosome products, and exosomes used to treat conditions in humans are regulated as drugs and biologics subject to premarket review. See our review of whether exosomes are FDA-approved and Empire’s article on what professionals should know about exosome injection.
- Injectable polynucleotide and PDRN products. Rejuran® and comparable polynucleotide injectables have no U.S. approval or clearance. Unapproved, not off-label.
- Profhilo®. Not approved here and not lawfully injectable. In July 2026 Evolus licensed U.S. rights from IBSA and took on the development work required for approval — worth saying, because it dates your answer.
- Restylane Skinboosters and Juvéderm® Volite. The Skinbooster line has never been approved here, and Volite is the ex-U.S. name for the gel FDA approved as SKINVIVE™ by Juvéderm® — there is no U.S. approval under the Volite name. FDA has also warned against unapproved imported Juvéderm Ultra 2, 3 or 4.
Then offer the approved anchor rather than nothing. SKINVIVE is the only FDA-approved injectable filler here with an intradermal skin-smoothness indication — cheek smoothness in adults over 21 since May 2023, plus neck lines since June 2026 — and it is not approved for “glass skin,” glow or whole-face use. The category distinctions patients blur are in our comparison of skin boosters and dermal fillers, and collagen stimulation is the frame where structure is the goal.
Building the skin-quality service line
Define the attributes, then name services for the procedure
“Skin quality” is a commercially powerful phrase with no agreed clinical definition: a 2026 systematic review of 903 studies found subjective endpoints made up 87% of observations, with 7 to 17 competing definitions per attribute. Define yours in writing. Pick the attributes you will assess and treat — hydration and barrier, texture, pigment evenness, laxity — and attach each to a modality you are trained to deliver: medical-grade peels, microneedling, energy-based tightening, intradermal hyaluronic acid within its approved indication, biostimulators where structure is the goal. A menu line called “glass skin facial” promises a result with no validated measure behind it; “superficial medical peel” promises a procedure you can deliver every time.
Structure plans and price without promises
Maintenance-minded patients buy a plan, not a visit, so sell a defined course of treatment with a set number of visits and a scheduled review point — and sell the review, not the result. Memberships and treatment plans smooth revenue and raise rebooking. Keep the compliance floor absolute: no guarantees, no promised outcomes, no satisfaction guarantee, no implication that a documented result is typical. And resist the price anchor: there is no defensible published comparison of Korean and U.S. per-visit pricing, so price on your own cost and market.
Train the staff and photograph honestly
Whoever takes the call needs to say “that product has no U.S. approval” accurately and without apology, so keep a one-page internal reference of category statuses with dates, review it quarterly, and rehearse the decline until it stops sounding like a refusal. Coordinators should also know which requests go to a clinician before a price is quoted.
Subtle outcomes get oversold by accident, because the physics is against you: an occlusive film raises measured specular gloss within minutes, and film-forming cosmetics have been shown to raise instrument-measured under-eye smoothness 15 minutes after application. A radiance photograph taken after moisturizer is a photograph of the moisturizer. Cleanse and wait before capture, fix lighting, angle, distance and camera, and record the interval since the last product applied. Never turn a photograph into a marketing promise.
Frequently asked questions
Why are patients asking for Korean treatments?
Because many of them, or people they know, have had one. Korea treated 2.01 million foreign patients in 2025, up 71.9% on the year before, with dermatology accounting for 62.9% of them and the United States among the leading source countries. That exposure is mostly skin work in outpatient clinics, which is why requests arrive framed as skin quality rather than lines or volume.
What is skin quality in aesthetic medicine?
A useful umbrella term with no agreed definition: a 2026 systematic review of 903 studies found 7 to 17 competing definitions per attribute, with subjective endpoints accounting for 87% of observations. Define it for your own protocols as a short list of assessable attributes, documented separately rather than as one global “glow.”
How do I respond to a request for an unapproved product?
Name the status precisely, date it, and substitute: say the product has no U.S. approval, distinguish that from off-label use of an approved product, explain what is approved for the same goal, and document it. Injectable polynucleotide and PDRN products, Profhilo®, Restylane Skinboosters and exosome products all sit in that category, and the classes are covered in our explainer on polynucleotides.
Are patients moving away from filler?
Partly, and the honest answer is smaller than the narrative. No society survey publishes a filler-dissolving statistic; the strongest society-sourced figure is AAFPRS’s 2023 member survey, in which 24% of responding surgeons said looking unnatural or overdone is patients’ biggest fear. AbbVie reported 2025 global Juvéderm® revenue down 15.3%, a demand signal rather than clinical evidence, while ISAPS 2024 showed HA filler volume still growing modestly as toxin fell.
Where to build this into your practice
The hands-on Facial Contouring Injectables: Sculptra®, Radiesse®, Exosomes & PDRN Certification Workshop covers preparation, dilution and injection technique for Sculptra® poly-L-lactic acid and Radiesse® calcium hydroxylapatite, integration of exosome therapy and PDRN into skin rejuvenation protocols, layering with PDO threads, PRP and PRF, cannula technique, and complication management. It is open to MD/DO, DMD/DDS, NP, PA and RN attendees, and is non-CME. For the skin side of the menu, Complete Facial Aesthetic Training includes medical-grade chemical peels and microneedling.
Owners building a service line rather than adding one procedure should look at Empire Memberships, which bundle a set number of hands-on workshops by tier — Platinum, Diamond and Sapphire — with medical practice business and marketing training, coaching support and livestream question-and-answer sessions.
For layered protocol design at faculty level, the Empire Holiday Gala on Thursday, December 3, 2026 in New York City includes a live stage demonstration by Dr. Lanna Cheuck, DO, FACS — “Dr. Lanna’s Celebrity Non-Surgical Facelift™ — The Multilayer K-Beauty Stack.” Her protocol, described on Empire’s page as inspired by advanced Korean aesthetic principles, sequences injectables, collagen biostimulators, energy-based devices, resurfacing and regenerative therapies to each patient’s anatomy rather than relying on excessive filler, and the demonstration shows an LHALA Peel followed by a customized skin-tox mesotherapy treatment. Anatomy first, layers second, filler last is the logic your consultation script should carry.
